Novartis | NOVN - Loan Capital


Novartis reported $37.45B in Loan Capital for its fiscal quarter ending in March of 2026.





Loan Capital Change Date
AbbVie USD 58.94B 4.03B Dec/2025
Alcon AG USD 4.16B 434M Mar/2026
Almirall EUR 324.81M 61.32M Dec/2025
Amgen USD 51.89B 1.88B Mar/2026
AstraZeneca USD 25.96B 177M Mar/2026
Autolus Therapeutics Ltd USD 277.27M 7.07M Mar/2026
Bayer EUR 30.68B 1.15B Mar/2026
Biogen USD 6.29B 1.7M Mar/2026
Bristol-Myers Squibb USD 42.15B 698M Mar/2026
Eli Lilly USD 39.37B 1.5B Mar/2026
Fresenius EUR 9.22B 1.58B Dec/2025
Fresenius Medical Care EUR 5.74B 895.27M Mar/2026
Genmab DKK 5.14B 5.01B Dec/2025
Gilead Sciences USD 20.86B 1.27B Mar/2026
GlaxoSmithKline GBP 14.01B 696M Mar/2026
GRIFOLS EUR 9.08B 612M Mar/2026
Hikma Pharmaceutical USD 1.49B 692M Dec/2025
J&J USD 37.53B 1.91B Mar/2026
Lakefront Biotherapeutics EUR 4.85M 335K Mar/2026
Lonza CHF 3.88B 323M Dec/2025
Merck EUR 10.8B 72M Mar/2026
Merck USD 46.67B 77M Mar/2026
Novartis USD 37.45B 7.86B Mar/2026
Novartis USD 29.59B 5.35B Dec/2025
Novo Nordisk DKK 119.17B 231M Mar/2026
Orion EUR 110.6M 4.7M Mar/2026
Pfizer USD 60.57B 1.08B Mar/2026
Philips EUR 6.89B 43M Mar/2026
Recordati EUR 1.76B 373.2M Mar/2026
Regeneron Pharmaceuticals USD 1.99B 719.7M Mar/2026
Roche Holding CHF 27.43B 966M Dec/2025
Sanofi EUR 13.84B 1.88B Mar/2026
UCB EUR 2.18B 634M Dec/2025